Showing results (11-20 of 38) with videos related to
Sort By:
Pageof 4
Annual Review of Pharmacology and Toxicology|October 29, 2013
GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autismUwe Rudolph, Hanns MöhlerF1000Research|February 25, 2017
Disinhibition, an emerging pharmacology of learning and memoryHanns Möhler, Uwe RudolphNeuropharmacology|August 3, 2017
Impact on GABA systems in monogenetic developmental CNS disorders: Clues to symptomatic treatmentDietmar Benke, Hanns MöhlerAnnual Review of Pharmacology and Toxicology|January 28, 2004
Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse geneticsUwe Rudolph, Hanns MöhlerCurrent Opinion in Pharmacology|December 27, 2005
GABA-based therapeutic approaches: GABAA receptor subtype functionsUwe Rudolph, Hanns MöhlerCurrent Protocols in Pharmacology|February 2, 2012
Benzodiazepine binding to GABA(A) receptorsDietmar Benke, Hanns MöhlerInternational Journal of Oncology|September 2, 2014
Redox-directed cancer therapeutics: Taurolidine and Piperlongumine as broadly effective antineoplastic agents (review)Hanns Möhler, Rolf W Pfirrmann, Karl FreiNeuroscience Letters|August 17, 2002
Seizure suppression by adenosine A(2A) receptor activation in a rat model of audiogenic brainstem epilepsyAlexander Huber, Martin Güttinger, Hanns Möhler, et al.Trends in Pharmacological Sciences|July 21, 2009
GABAergic analgesia: new insights from mutant mice and subtype-selective agonistsHanns Ulrich Zeilhofer, Hanns Möhler, Alessandra Di LioAnticancer Research|May 27, 2004
Taurolidine-Fibrin-Sealant-Matrix using spray application for local treatment of brain tumorsRuediger Stendel, Louis Scheurer, Kathrin Schlatterer, et al.Pageof 4